31 Results

People

  1. Intlekofer
    Intlekofer
  2. Palomba
    Palomba
  3. Zelenetz
    Zelenetz
  4. Hamlin
    Hamlin
  5. Noy
    Noy
  6. Horwitz
    Horwitz
  7. Kumar
    Kumar
  8. Moskowitz
    Moskowitz
  9. Caron
    Caron
  10. Vardhana
    Vardhana

Groups

  1. Center for Hematologic Malignancies (31)
  2. Department of Medicine (31)
  3. GSK Faculty (31)
  4. Hematologic Malignancies Research (31)
  5. Hematologic Malignancies, Division of (31)
  6. Human Oncology and Pathogenesis Program (31)
  7. Lymphoma (31)
  8. Population Sciences Research Program (27)
  9. Survivorship Research (22)
  10. Sloan Kettering Institute Postdocs (21)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Maria Palomba"
  4. "Andrew Intlekofer"
  5. "Andrew Zelenetz"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (4)
Groups
  1. Center for Hematologic Malignancies (31)
  2. Department of Medicine (31)
  3. GSK Faculty (31)
  4. Hematologic Malignancies Research (31)
  5. Hematologic Malignancies, Division of (31)
  6. Human Oncology and Pathogenesis Program (31)

More Groups

People
  1. Andrew Intlekofer (31)
  2. Andrew Zelenetz (31)
  3. Maria Palomba (31)
  4. Ariela Noy (27)
  5. Paul Hamlin (27)
  6. Alison Moskowitz (26)

More People

Years
  1. 2023 (12)
  2. 2022 (3)
  3. 2021 (1)
  4. 2020 (2)
  5. 2019 (2)
  6. 2018 (1)

More Years

Publications
  1. Blood (22)
  2. Hematological Oncology (3)
  3. Blood Advances (2)
  4. Blood Cancer Journal (1)
  5. Journal of Clinical Oncology (1)
  6. Laboratory Investigation (1)

More Publications

Publishers
  1. American Society of Hematology (24)
  2. Wiley Blackwell (3)
  3. Nature Publishing Group (2)
  4. American Society of Clinical Oncology (1)
  5. Nature Research (1)

Results (31)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era
    Meeting Abstract

    Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save